[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f982b92a1ebc89a9f0de6d21696c835fa101c8b2be3daaee5d1d22ac9ea4a9a2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754498040,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136251013,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f982b92a1ebc89a9f0de6d21696c835fa101c8b2be3daaee5d1d22ac9ea4a9a2"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is Flawed",
    "summary": "Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues suggest caution. Click for my SMMT update.",
    "url": "https://finnhub.io/api/news?id=87020c4917ed777c90037d83cad5114f1714bedb22912f1a0d7446dd9affb844",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754493188,
      "headline": "Summit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is Flawed",
      "id": 136240337,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/831416116/image_831416116.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues suggest caution. Click for my SMMT update.",
      "url": "https://finnhub.io/api/news?id=87020c4917ed777c90037d83cad5114f1714bedb22912f1a0d7446dd9affb844"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says",
    "summary": "Halozyme Therapeutics (HALO) fiscal 2025 guidance update following Q2 revenue beat driven by royalty",
    "url": "https://finnhub.io/api/news?id=80db0f37a19db9210f4e13b604cc3ea91af444c8affc710659ba350b33b8714f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754492722,
      "headline": "Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says",
      "id": 136239090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics (HALO) fiscal 2025 guidance update following Q2 revenue beat driven by royalty",
      "url": "https://finnhub.io/api/news?id=80db0f37a19db9210f4e13b604cc3ea91af444c8affc710659ba350b33b8714f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. (MRK) Slid on Weaker Market Sentiment and Concerns About Drug Pipeline",
    "summary": "Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In 2025’s second quarter, tariffs triggered market declines and recession fears, but a pause in tariffs sparked a historic rally as earnings remained resilient. In the second quarter […]",
    "url": "https://finnhub.io/api/news?id=cb9ce6c1204dbc55f4516ccc360de769d6cdd2e1d6dc0c906b9d1ac36722b657",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481698,
      "headline": "Merck & Co. (MRK) Slid on Weaker Market Sentiment and Concerns About Drug Pipeline",
      "id": 136237288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In 2025’s second quarter, tariffs triggered market declines and recession fears, but a pause in tariffs sparked a historic rally as earnings remained resilient. In the second quarter […]",
      "url": "https://finnhub.io/api/news?id=cb9ce6c1204dbc55f4516ccc360de769d6cdd2e1d6dc0c906b9d1ac36722b657"
    }
  },
  {
    "ts": null,
    "headline": "Stock Picks From Seeking Alpha's July 2025 New Analysts",
    "summary": "Meet Seeking Alpha's 44 new analysts and explore their top stock picks.",
    "url": "https://finnhub.io/api/news?id=84982e002f0ee327962685350bf07b1b5d10c43d1c34c7d77ce0be101603b257",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754476200,
      "headline": "Stock Picks From Seeking Alpha's July 2025 New Analysts",
      "id": 136236936,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281294964/image_1281294964.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Meet Seeking Alpha's 44 new analysts and explore their top stock picks.",
      "url": "https://finnhub.io/api/news?id=84982e002f0ee327962685350bf07b1b5d10c43d1c34c7d77ce0be101603b257"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning.",
    "url": "https://finnhub.io/api/news?id=c9848f5fa0823655cf6855a3002c110f8dbaf6a107bab626fe3d22a51d8018c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754474400,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 136232245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning.",
      "url": "https://finnhub.io/api/news?id=c9848f5fa0823655cf6855a3002c110f8dbaf6a107bab626fe3d22a51d8018c5"
    }
  },
  {
    "ts": null,
    "headline": "PBM reform was dropped from Trump’s spending bill. It could have saved billions.",
    "summary": "The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.",
    "url": "https://finnhub.io/api/news?id=f260d99e1047a5d2a866c20befa2d78398be0251d1fc94d18dda01c1826769c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754467200,
      "headline": "PBM reform was dropped from Trump’s spending bill. It could have saved billions.",
      "id": 136237289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.",
      "url": "https://finnhub.io/api/news?id=f260d99e1047a5d2a866c20befa2d78398be0251d1fc94d18dda01c1826769c7"
    }
  }
]